Pipeline
| TARGET | INDICATION | PROGRAM | PRECLINICAL | PHASE I | PHASE II | PHASE III | APPROVAL |
|---|---|---|---|---|---|---|---|
| Ataxia | Late-Onset | SLX-100 |  | 2026 | |||
| Pediatric | SLX-200 |  | 2028 | ||||
| Nerve Injuries | CIPN | SLX-300 |  | 2029 | |||
| Trauma | SLX-400 |  | TBD |
For SLX-100 and SLX-200, we will be referencing safety and dosing from previously published studies not conducted by Solaxa in our 505b2 expedited regulatory submission
Issued patent protection
- through 2036: 4-Aminopyridine
- through 2038: Confidential